Pucci, Perla http://orcid.org/0000-0003-1264-3487
Lee, Liam C.
Han, Miaojun
Matthews, Jamie D. http://orcid.org/0000-0002-2980-8615
Jahangiri, Leila
Schlederer, Michaela
Manners, Eleanor
Sorby-Adams, Annabel
Kaggie, Joshua http://orcid.org/0000-0001-6706-3442
Trigg, Ricky M.
Steel, Christopher
Hare, Lucy
James, Emily R. http://orcid.org/0000-0001-9731-5508
Prokoph, Nina http://orcid.org/0000-0002-6429-9895
Ducray, Stephen P. http://orcid.org/0000-0001-6407-1906
Merkel, Olaf http://orcid.org/0000-0001-5089-344X
Rifatbegovic, Firkret http://orcid.org/0000-0002-9956-2382
Luo, Ji http://orcid.org/0000-0001-5063-1626
Taschner-Mandl, Sabine http://orcid.org/0000-0002-1439-5301
Kenner, Lukas http://orcid.org/0000-0003-2184-1338
Burke, G. A. Amos http://orcid.org/0000-0003-2671-9972
Turner, Suzanne D. http://orcid.org/0000-0002-8439-4507
Funding for this research was provided by:
Neuroblastoma UK (NBUKTurner19)
CHILDREN with CANCER UK (16-209)
Cancer Research UK (C9685/A25117)
Article History
Received: 28 October 2022
Accepted: 11 April 2024
First Online: 23 April 2024
Competing interests
: G.A.A.B. has received institutional consultancy fees from Roche, Takeda, Novartis, and Janssen. All other authors have no conflicts of interest to declare.